On January 4, 2019, Sana Biotechnology became the latest regenerative medicine company to enter the marketplace, founded by former Juno Therapeutics executives Hans Bishop and Steve Harr, among other all-star executives. With operations in Seattle, WA, Cambridge, MA and San Francisco, CA, the company will be focused on creating engineered cells as medicines for patients.
Based on preliminary company statements, Sana seems to be interested in reproducing the business model and the financial success that characterized Juno Therapeutics – specifically, its ability to attract top talent from across the marketplace, accumulate investor funds, and exit for a major windfall. [Read more…]